Hyunsun Jo
Chief Executive Officer Pin Therapeutics
Founder and Chief Executive Officer of Pin Therapeutics, Korea (2017-)
Founding Partner of Embedbio (The Early-Stage Investment Company Builder Specialized in Biotech and Healthcare Sectors), Palo Alto, CA, USA
Postdoctoral Fellow of Medicine, J David Gladstone Institute (UCSF), CA, USA
PhD of Biological Sciences, Seoul National University (Metabolic Diseases), Korea
Bachelor of Chemistry, Seoul National University, Korea
Bachelor of Biological Sciences, Seoul National University, Korea
Seminars
Thursday 11th June 2026
Panel Discussion: Navigating Venture Capital Funding & Structuring Strategic Collaborations in South Korea to Accelerate Biotech Growth, Secure Investment & Expand Global Reach
9:00 am
- Understanding Korean venture capital expectations to tailor fundraising strategies, attract competitive capital and enable sustainable biotech scaling
- Identifying how recent deals highlight investor priorities for emerging modalities including novel ligases, non-oncology-targeted degraders, and DACs to guide platform positioning and increase funding success
- Examining how early-stage proof-of-concept studies validate technology, strengthen investor confidence, and accelerate pharma partnership commitments
- Discussing how to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your TPD candidate
Thursday 11th June 2026
Harnessing a Novel E3 Ligase-Targeting DAC to Overcome Hematologic Toxicity in ADCs
12:00 pm
- Engineering a degrader payload that recruits a novel E3 ligase to enable selective degradation of tumor-driving proteins with reduced hematologic off-target effects
- Advancing beyond traditional cytotoxic payloads by leveraging targeted protein degradation to minimize collateral damage to healthy blood cell lineages
- Unlocking a new class of safer, next-generation DACs with differentiated biological mechanisms to improve therapeutic index across hematologic indications
